Researchclopedia
Research
Researchers
Institutions
Topics
Submit
About
Search...
⌘
K
Command Palette
Search for a command to run...
Back to research
LBA13 Enozertinib (ORIC-114), a highly selective, brain penetrant EGFR and HER2 inhibitor, in EGFR Exon 20 mutant NSCLC: Randomized dose optimization and CNS activity
2025
0 citations
Journal Article
Field-Weighted Citation Impact:
0.00
LBA13 Enozertinib (ORIC-114), a highly selective, brain penetrant EGFR and HER2 inhibitor, in EGFR Exon 20 mutant NSCLC: Randomized dose optimization and CNS activity | Researchclopedia
·
Duke Medical Center
R. Dziadziuszko
·
Gdańsk Medical University
M. Krebs
·
The Christie NHS Foundation Trust
Joshua K. Sabari
·
NYU Langone Health
A. Spira
·
Virginia Cancer Specialists
C. Kim
·
Georgetown University Medical Center
M.L. Cheng
·
University of California, San Francisco
A. Weber
·
Arena Pharmaceuticals (United States)
K. Velastegui
·
Arena Pharmaceuticals (United States)
Anneleen Daemen
·
Sunesis (United States)
J. Wang
·
Arena Pharmaceuticals (United States)
E. Chow Maneval
·
Arena Pharmaceuticals (United States)
PS Multani
·
Arena Pharmaceuticals (United States)
Myung-Ju Ahn
·
Sungkyunkwan University